Deciphering the therapeutic stem cell strategies of large and midsize pharmaceutical firms

Regenerative Medicine

Volumn 9, Issue 4, 2014, Pages 479-495

  Vertès, Alain A ^a,b  

^a LONDON BUSINESS SCHOOL   (United Kingdom)

^b NxR Biotechnologies GmbH   (Switzerland)

Author keywords

big pharma; cytotherapeutics; disruptive innovation; licensing and partnerships; midsize pharmaceutical firms; radical innovation; stem cells; technology adoption; technology deployment

Indexed keywords

BIOTECHNOLOGY; CELL THERAPY; DECISION MAKING; DRUG INDUSTRY; ECONOMIC EVALUATION; GOVERNMENT REGULATION; HEALTH CARE POLICY; HEMATOPOIETIC STEM CELL; HUMAN; MEDICAL RESEARCH; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; SOCIAL MARKETING; STEM CELL TRANSPLANTATION; STRATEGIC PLANNING; ALLOGRAFT; BIOLOGICAL THERAPY; CULTURE TECHNIQUE; ECONOMICS; PROCEDURES; STEM CELL;

ALLOGRAFTS; CELL CULTURE TECHNIQUES; CELL- AND TISSUE-BASED THERAPY; DRUG INDUSTRY; HUMANS; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84906730217     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.14.16     Document Type: Review

References (119)

1. Cambrosio A, Keating P. Between fact and technique: The beginnings of hybridoma technology. J. Hist. Biol. 25, 175-230 (1992
2. Glassman RH, Sun AY. Biotechnology: Identifying advances from the hype. Nat. Rev. Drug Discov. 3, 177-183 (2004
3. Jack A. Merck to cut 8,500 more jobs. The Financial Times, 2 October (2013
4. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9, 767-774 (2010
5. Aggarwal S. What's fueling the biotech engine-2012 to 2013. Nat. Biotechnol. 32, 32-39 (2014
6. Mullin E. Biotech products in Big Pharma clinical pipelines have grown dramatically. Fierce Biotech, 18 November (2013
7. Assink M. Inhibitors of disruptive innovation capability: A conceptual model. Eur. J. Innov. Manag. 9, 215-233 (2006
8. Christensen CM. The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail. Harvard Business School Press, Boston, MA, USA (1997
9. Ettlie J, Bridges WP, O'Keefe RD. Organization strategy and structural differences for radical versus incremental innovation. Manag. Sci. 30, 682-695 (1984
10. Hamel G, Prahalad CK. Corporate imagination and expeditionary marketing. Harv. Bus. Rev. 69, 81-92 (1991
11. Henderson R. Underinvestment and incompetence as responses to radical innovation: Evidence from the photolithographic alignment equipment industry. Rand J. Econ. 24, 248-270 (1993
12. Leifer R, Colarelli O'Connor G, Rice M. Implementing radical innovation in mature firms: The role of hubs. Acad. Manag. Exec. 15, 102-113 (2001
13. Stringer R. How to manage radical innovation. Calif. Manag. Rev. 42, 70-88 (2000
14. Vertès AA. Knowing when to adopt stem cell technologies. MedNous, July-August (2010
15. Vertès AA. Time to engage with stem-cell therapeutics. MedNous, April (2012
16. Ewing R. Khosla chides Big Oil for lack of biofuels appetite. Reuters, 6 June 2011
17. Lane J. BP Biofuels: Time for "the really hard yards" in biofuels commercialization. Biofuels Digest, 13 March (2013
18. Linton JD, Walsh ST. Extracting value form learning curves: Integrating theory and practice. Creativity Innov. Manag. 22, 10-25 (2013
19. Vertès AA, Inui M, Yukawa H. Implementing biofuels on a global scale. Nat. Biotechnol. 24, 761-764 (2006
20. Harding R. A mysterious divergence. The Financial Times, 25 July (2013
21. Bruneel J, Van De Velde E, Clarysse B, Gemmel P. Improving the success of radical innovation projects within established firms: Engaging employees across different hierarchal levels. Technol. Anal. Strateg. Manag. 24, 951-965 (2012
22. Vertès AA. Creating an Effective Clinical Delivery Plan for Cell Therapies. Genetics Policy Institute, FL, USA (2009
23. Vertès AA. Adoption of therapeutic stem cell technologies by large pharmaceutical companies. In: The Delivery of Regenerative Medicines and Their Impact on Healthcare. Prescott CD, Polak J (Eds). CRC Press, FL, USA, 153-175 (2010
24. Aldridge S. Regenerative medicine: Small steps towards the great leap forward. Pharmafile, 16 August 2010
25. Netterwald J. Stem cell technologies boost regenerative medicine: Symbiotic relationship expected to lead to new therapies for diseases. Genet. Eng. News 29, 18 (2009
26. Vertès AA. Roche's perspective on how the cell and gene therapy sector is reaching maturity and driving value. Presented at: Phacilitate. Cell and Gene Therapy Forum, 2009. Washington, DC, USA, 26-28 January 2009
27. Colarelli O'Connor G, McDermott CM. The human side of radical innovation. J. Eng. Technol. Manag. 21, 11-30 (2004
28. Villiger R, Bogdan B. Dissecting monoclonal antibody mega-deals. mAbs 1, 172-178 (2009
29. Alsberg E, Rowley JA. Technologies for enhancing tissue engineering: Materials and environments for guiding stem cell function. Preface. Tissue Eng. A 15, 203-204 (2009
30. Coutu DL, Moïra F, Galipeau J. Mesenchymal stem cells and tissue repair. In: Regenerative Therapy Using Blood-Derived Stem Cells. Allan DS, Strunk D (Eds). Humana Press, New York, NY, USA, 35-51 (2012
31. Rossbach M, Hadenfeld M, Brüstle O. Industrial applications of stem cells. In: Translational Stem Cell Research. Hug K, Hermerèn G (Eds). Humana Press, New York, NY, USA, 91-103 (2011
32. Vanek PG. Lonza cell therapy. Future Med. 3, 237-241 (2008
33. Bergman K, Graff GD. The global stem cell patent landscape: Implications for efficient technology transfer and commercial development. Nat. Biotechnol. 25, 419-424 (2007
34. Konski AF, Spielthenner DJ. Stem cell patents: A landscape analysis. Nat. Biotechnol. 27, 722-726 (2009
35. Boregowda SV, Phinney DG. MSCs: Paracrine effects. In: Mesenchymal Stromal Cells: Biology and Clinical Applications. Hematti P, Keating P (Eds). Springer, New York, NY, USA, 145-167 (2013
36. Caplan A, Bruder SP. Mesenchymal stem cells: Building blocks for molecular medicine in the 21st century. Trends Mol. Med. 7, 259-264 (2001
37. Carroll J. J&J gambles $12.5 million in rare Big Pharma bet on a stem cell therapy. Fierce Biotech, 6 January (2014
38. Anonymous. Medtronic Annual Report: Transforming for Growth. Medtronic, MN, USA (2012
39. Vinas T Medtronic stakes position in cardiac stem-cell therapy. www.industryweek.com/archive/medtronic-stakes-position-cardiac-stem-cell- Therapy (2005
40. Anonymous. Cellerix raises €27 million in a first closing. Fierce Biotech, 11 November (2009
41. Anonymous. Promethera raises $31.4m to progress progenitor cell therapy for liver diseases. Genet. Eng. News, 28 March (2012
42. Anonymous. Celgene touts pipeline, stem cell drug at R&D day. Fierce Biotech, 9 April (2010
43. Anonymous. Celgene Annual Report. Celgene, NJ, USA (2011
44. Mullin E. ViaCyte, Inc. raises $10.6 million in a private financing to support clinical development of its cell therapy product for insulin dependent diabetes. Fierce Biotech, 10th July (2013
45. Ben-David U, Gan QF, Golan-Lev T et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-Throughput screen. Cell stem cell 12, 167-179 (2013
46. Lou KJ. Small molecules vs. teratomas. Sci. Bus. Exch. 6, 1-2 (2013
47. Anonymous. Roche to lead Israel stem cell consortium. BioJerusalem, 3 April 2011
48. Vertès AA. Syndicate innovation venturing. Challenges 3, 70-83 (2012
49. Thompson K Cell Therapy Catapult to work with GlaxoSmithKline on Cell Therapies (2013). www.innovateuk.org/-/cell-Therapy-catapult-To-work-with- glaxosmithkline-on-cell-Therapies
50. Haussecker D. The business of RNAi in 2012. Mol. Ther. Nucleic Acids 1, e8 (2012
51. Anonymous. The Future of Monoclonal Antibodies-Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis, GBI Research (2009). www.gbiresearch.com
52. Tirrell M, Lachapelle T Pharmasset sets Inhibitex-To Achillion drugmakers deals: Real M&A. Business Week, 22nd November (2011
53. Christensen CM, Kaufman SP, Shih WC. Innovation killers: How financial tools destroy your capacity to do new things. Harv. Bus. Rev. 86(1), 98-105, 137 (2008
54. Sheridan C. Gene therapy finds its niche. Nat. Biotechnol. 29, 121-128 (2011
55. Yla-Herttuala S. Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European union. Mol. Ther. 20, 1831-1832 (2012
56. Berkrot B. Gilead could have had Pharmasset cheap: Founder. Reuters, 22 November 2011
57. Senior M. Sovaldi makes blockbuster history, ignites drug pricing unrest. Nat. Biotechnol. 32(6), 501-502 (2014
58. Kessel M. The problems with today's pharmaceutical business-An outsider's view. Nat. Biotechnol. 29, 27-33 (2011
59. Harrison C. Patent watch: The patent cliff steepens. Nat. Rev. Drug Discov. 10, 12-13 (2011
60. Mason C, Brindley DA, Culme-Seymour EJ, Davie NL. Cell therapy industry: Billion dollar global business with unlimited potential. Regen. Med. 6, 265-272 (2011
61. Mason C, McCall MJ, Culme-Seymour EJ et al The global cell therapy industry continues to rise during the second and third quarters of 2012. Cell Stem Cell 11, 735-739 (2012
62. Hamel G The ghost of the Politburo (2010). www.managementexchange.com/ barrier/ghost-politburo
63. Herper M. A decade in drug industry layoffs. Forbes, 14th April (2011
64. Anonymous. Novo Nordisk Annual Report 2005. Novo Nordisk, Bagsværd, Denmark (2005
65. Anonymous. Novo Nordisk Annual Report 2010. Novo Nordisk, Bagsværd, Denmark (2010
66. Bonner-Weir S, Weir GC. New sources of pancreatic beta-cells. Nat. Biotechnol. 23, 857-861 (2005
67. Guo T, Hebrok M. Stem cells to pancreatic beta-cells: New sources for diabetes cell therapy. Endocr. Rev. 30, 214-227 (2009
68. Vertès AA. Stem cell commmercialization and partnering-A GTCBio conference. Reuters, 20 April 2012
69. Vertès AA World stem cell summit 2012. Reuters, December (2012
70. Danneels E. Disruptive technology reconsidered: A critique and research agenda. J. Prod. Innov. Manag. 21, 246-258 (2004
71. Bull ND, Martin KR. Concise review: Toward stem cell-based therapies for retinal neurodegenerative diseases. Stem Cells 29, 1170-1175 (2011
72. Coffey P. Stemming vision loss with stem cells: Seeing is believing. Future Med. 4, 505-507 (2009
73. Jenq RR, Van Den Brink MR. Allogeneic haematopoietic stem cell transplantation: Individualized stem cell and immune therapy of cancer. Nat. Rev. Cancer 10, 213-221 (2010
74. Mimeault M, Batra SK. Concise review: Recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells 24, 2319-2345 (2006
75. Nuzzi R, Gunetti M, Rustichelli D et al. Effect of in vitro exposure of corticosteroid drugs, conventionally used in AMD treatment, on mesenchymal stem cells. Stem Cell Int. 2012, 946090 (2012
76. Jimenez J. The CEO of Novartis on growing after a patent cliff. Harv. Bus. Rev. 90, 39-42 (2012
77. Baron F, Storb R. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: A review. Springer Semin. Immunopathol. 26, 71-94 (2004
78. Gluckman E. History of cord blood transplantation. Bone Marrow Transplant. 44, 621-626 (2009
79. Thomas ED. Bone marrow transplantation: A review. Semin. Hematol. 36, 95-103 (1999
80. Anonymous. Baxter initiates Phase III adult stem cell clinical trial for chronic cardiac condition. Baxter Press Release (2012
81. Christopherson KW 2nd, Paganessi LA, Napier S, Porecha NK. CD26 inhibition on CD34+ or lineage-human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-Term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev. 16, 355-360 (2007
82. Robinson SN, Simmons PJ, Thomas MW et al. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rgamma(null) mice. Exp. Hematol. 40, 445-456 (2012
83. Sackstein R. Re: "Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rgamma(null) mice". Exp. Hematol. 40, 518-519 (2012
84. Bayon Y, Ellison S, Vertès AA et al. Commercialization of regenerative products: The academic-industry partnership. Tissue Eng. B doi:10.1089/ten.teb.2012.0683 (2013) (Epub ahead of print
85. Castiaux A. Radical innovation in established organizations: Being a knowledge predator. J. Eng. Technol. Manag. 24, 36-52 (2007
86. Anonymous. 2010 Cephalon Annual Report. Cephalon, PA, USA (2010
87. Berkrot B. Interview: Mesoblast's Cephalon deal was late CEO's vision. Reuters, 2 March (2011
88. Vertès AA. The cell therapy commercialisation summit. Reuters, 21st September (2011
89. Kresge N, Langreth R. Teva bets on stem cells, cancer in $6.2 billion bid for Cephalon. Bloomberg, 3rd May (2011
90. Crunkhorn S. Deal watch: Shire increases focus on regenerative medicine. Nat. Rev. Drug Discov. 11(6), 430 (2012
91. Tozer D. The story of Advanced BioHealing: Commercializing bioengineered tissue products. Future Med. 6, 157-161 (2011
92. Anonymous. Shire adds new technology platform and phase 2 product candidate to its Regenerative Medicine business. Shire Press Release, 12 April (2012
93. Palmer E. Shire cuts Dermagraft, takes $650 million loss. FiercePharma, 17 January (2014
94. Taupin P. OTI-010 Osiris Therapeutics/JCR Pharmaceuticals. Curr. Opin. Investig. Drugs 7, 473-481 (2006
95. Bird J. Japan Pharma: Peer set overview. Datamonitor, London, UK (2012
96. Kobayashi A. Launch of a National Mandatory Chronic Disease Prevention Program in Japan. Dis. Manag. Health Outcomes 16(4), 217-225 (2008
97. Anonymous. Dainippon invests in Retina Institute, gets stem cell technology. BioSpectrum, 1st April (2013
98. Bushell-Embling D Aussie stem cell firms jump on Japan fast-Track (2013). http://lifescientist.com.au/content/biotechnology/article/ aussie-stem-cell- firms-jump-on-japan-fast-Track-784414693
99. Cyranoski D. Japan to offer fast-Track approval path for stem cell therapies. Nat. Med. 19, 510 (2013
100. Anonymous Cell Replacement Therapy Using ES Cells: Potential Application to the Treatment of Parkinson's Disease, Kyowa Hakko Kogyo Co. Ltd, Tokyo, Japan (2000
101. Kunisato A, Wakatsuki M, Kodama Y, Shinba H, Ishida I, Nagao K. Generation of induced pluripotent stem cells by efficient reprogramming of adult bone marrow cells. Stem Cells Dev. 19, 229-238 (2010
102. Toyooka Y, Tsunekawa N, Akasu R, Noce T. Embryonic stem cells can form germ cells in vitro. Proc. Natl Acad. Sci. USA 100, 11457-11462 (2003
103. Imamura M, Aoi T, Tokumasu A et al. Induction of primordial germ cells from mouse induced pluripotent stem cells derived from adult hepatocytes. Mol. Reprod. Dev. 77, 802-811 (2010
104. Licata P. Biotech joint venture Azienda Farmaceutica-Università. Chiesi, spinoff in provetta. El Mundo, 24 April (2009
105. Culme-Seymour EJ, Davie NL, Brindley DA, Edwards-Parton S, Mason C. A decade of cell therapy clinical trials (2000-2010). Regen. Med. 7, 455-462 (2012
106. McGlynn M. Industry voices: A pivotal time for stem cell therapeutics, as first clinical data emerges. Fierce Biotech, 15 July (2013
107. McKernan R, McNeish J, Smith D. Pharma's developing interest in stem cells. Cell Stem Cell 6, 517-520 (2010
108. Gardner TA, Elzey BD, Hahn NM. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Hum. Vaccines Immunother. 8, 534-539 (2012
109. Staton T. Dendreon's Provenge sales disappoint once again with 17% decline. Fierce Pharma, 9 May (2013
110. Schulze U, Ringel M. What matters most in commercial success: First-in-class or best-in-class? Nat. Rev. Drug Discov. 12, 419-420 (2013
111. Barton-Burke M, Dwinell DM, Kafkas L et al. Graft-versus-host disease: A complex long-Term side effect of hematopoietic stem cell transplant. Oncology (Williston Park) 22, 31-45 (2008
112. Gratwohl A, Niederwieser D. History of hematopoietic stem cell transplantation: Evolution and perspectives. Curr. Probl. Dermatol. 43, 81-90 (2012
113. Mason C, Dunnill P. A brief definition of regenerative medicine. Regen. Med. 3, 1-5 (2008
114. Baron F, Lechanteur C, Willems E et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-Tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol. Blood Marrow Transplant. 16, 838-847 (2010
115. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363, 1439-1441 (2004
116. von Bonin M, Stolzel F, Goedecke A et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 43, 245-251 (2009
117. Evans JB, Syed BA. New hope for dry AMD? Nat. Rev. Drug Discov. 12, 501-502 (2013
118. Stern JH, Temple S. Stem cells for retinal replacement therapy. Neurotherapeutics 8, 736-743 (2011
119. Clinical Trials database. http://clinicaltrials.gov